The United Kingdom today approved its first COVID-19 vaccine, created through a partnership between Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX).
The Medicines and Healthcare products Regulatory Agency (MHRA) approval came after a “rolling review” in which assessment takes place as the packages of data become available from ongoing studies on a staggered basis. The idea is to evaluate a promising medicine or vaccine as quickly as possible during public health emergencies, with MHRA scientists and clinicians reviewing everything from clinical trials to manufacturing and quality controls to supply chain and distribution conditions.
Get the full story at our sister site, Drug Discovery & Development.